Ebopiprant (OBE-022) is a first-in-class, potent, orally bioavailable and selective prostaglandin F2α (PGF2α) receptor antagonist, with Kis of 1 nM, 26 nM for human and rat FP receptors, respectively. It was designed to control preterm labour by reducing inflammation and uterine contractions as well as preventing cervical changes and fetal membrane rupture without causing the potentially serious vasoconstriction in the foetus.

纯度：≥98%

CAS：2005486-31-5